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The mammalian inflammatory response to infection involves the
induction of several hundred genes, a process that must be care-
fully regulated to achieve pathogen clearance and prevent the
consequences of unregulated expression, such as cancer. Recently,
microRNAs (miRNAs) have emerged as a class of gene expression
regulators that has also been linked to cancer. However, the
relationship between inflammation, innate immunity, and miRNA
expression is just beginning to be explored. In the present study,
we use microarray technology to identify miRNAs induced in
primary murine macrophages after exposure to polyriboi-
nosinic:polyribocytidylic acid or the cytokine IFN-. miR-155 was
the only miRNA of those tested that was substantially up-regu-
lated by both stimuli. It also was induced by several Toll-like
receptor ligands through myeloid differentiation factor 88- or
TRIF-dependent pathways, whereas up-regulation by IFNs was
shown to involve TNF- autocrine signaling. Pharmacological in-
hibition of the kinase JNK blocked induction of miR-155 in response
to either polyriboinosinic:polyribocytidylic acid or TNF-, suggest-
ing that miR-155-inducing signals use the JNK pathway. Together,
these findings characterize miR-155 as a common target of a broad
range of inflammatory mediators. Importantly, because miR-155 is
known to function as an oncogene, these observations identify a
potential link between inflammation and cancer.
cancer  inflammation  innate immunity  cytokines
The mammalian innate immune response provides a criticalfirst line of defense against pathogens. Detection of micro-
bial ligands is achieved through pattern recognition receptors,
such as the Toll-like receptors (TLRs) that are expressed at high
levels on macrophages and dendritic cells (1). TLRs have been
evolutionarily conserved from Drosophila to humans, with 11
mammalian TLRs known that recognize a wide range of distinct
chemical structures conserved in the microbial world (2). After
pathogen recognition, TLRs signal through adaptor proteins of
the myeloid differentiation factor 88 (MyD88) family to activate
several downstream signal transduction pathways, such as NF-
B, MAPKs, and members of the IRF family (3). Upon activa-
tion, these pathways coordinate the up-regulation of several
functionally distinct gene subsets (4) through both transcrip-
tional and posttranscriptional mechanisms (5). The proteins
encoded by these genes, such as the cytokines IFN-, IFN-, and
TNF-, are intended to initiate microbial clearance. However,
during pathological situations, these cytokines and the pathways
they activate can also play a role in such conditions as cancer and
autoimmunity (6–8). Although this ‘‘inflammatory’’ response to
infection has been studied in great detail, there remain several
regulatory aspects of this complex system that require further
identification and understanding.
Mammalian microRNAs (miRNAs) are noncoding RNA oli-
gonucleotides that have been highly conserved during evolution
and have recently emerged as potent regulators of gene expres-
sion (9). Approximately 500 genes encoding miRNAs have been
identified in mammals and have been shown to be both tempo-
rally and spatially regulated. miRNAs are transcribed by RNA
polymerase II as part of a primary transcript (10, 11) that is
processed by Drosha and DGCR8 into a smaller RNA molecule
that is exported from the nucleus by Exportin 5 (12, 13). Upon
reaching the cytoplasm, the primary miRNA undergoes further
processing by Dicer and is subsequently loaded onto the RISC
complex (14). Once in their mature form, miRNAs specifically
bind to 3 UTRs of target cellular mRNAs leading to either
mRNA degradation or inhibition of translation (9).
Functionally speaking, mammalian miRNAs play pivotal roles
in shaping cellular development and differentiation in various
tissues (15). Consequently, dysregulated miRNA levels are
associated with several types of malignancies including co-
lon, breast, and lung cancers (16–18). Cells of hematopoeitic
origin also express certain miRNAs that drive their development
(19, 20), and altered miRNA expression has been found in
leukocyte-derived tumors including pediatric Burkitt’s lym-
phoma and chronic lymphocytic leukemia (16, 17). Despite these
observations, it is presently unclear how miRNA expression
in leukocytes becomes altered during the onset of cellular
transformation.
Because of the profound influence of inflammatory stimuli on
gene expression, the innate immune response has the potential
to regulate miRNA levels. Recently, our group used microarray
technology to determine whether the TLR4 ligand lipopolysac-
charide (LPS) can affect miRNA expression in human THP-1
monocytes (21). Three miRNAs were up-regulated, including
miR-132, miR-146, and miR-155. Further characterization of
miR-146 revealed that it is regulated by NF-B and may function
as a negative regulator of IRAK1 and TRAF6 expression. Such
findings demonstrate that miRNAs levels can be altered by
bacterial endotoxin and may be involved in regulating innate
immune responses.
To test whether virally relevant stimuli induce expression of
specific miRNAs, we extended our microarray studies. miR-155
was identified as a specific target of both polyriboinosinic:polyri-
bocytidylic acid [poly(I:C)] and IFN-. Further investigation
revealed that several TLR ligands increased miR-155 expression
through either the MyD88 or TRIF signaling, whereas IFNs
required TNF- autocrine signaling to up-regulate miR-155.
Inhibition of JNK blocked both poly(I:C) and TNF- induction
of miR-155, indicating a role for MAPK signaling in the regu-
lation of miR-155 levels. Our findings reveal miR-155 as a
component of the inflammatory response and suggest that this
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oncogenic miRNAmay prove to be a link between inflammation
and cancer.
Results
Our observations started from a microRNA array screen per-
formed to identify miRNAs up-regulated by macrophages in
response to stimuli with relevance to viral infections. Macro-
phages were matured from murine bone marrow and stimulated
with either the synthetic viral intermediate, poly(I:C) (double-
stranded RNA), or the host antiviral response cytokine, IFN-.
After 6 h of treatment, total RNA was extracted and used to
determine the expression levels of 200 unique mouse and human
miRNAs in their mature forms. miR-155 was identified as the
only miRNA substantially induced both by poly(I:C) and IFN-
(Fig. 1A), and this was based on by using a P value of 0.01 as a
cutoff for significance. To confirm the validity of miR-155
induction, a portion of the RNA used for the microarray was
converted to cDNA and subjected to quantitative PCR (qPCR).
Consistent with the microarray findings, miR-155 was strongly
induced by poly(I:C) and IFN-, a result confirmed by Northern
blotting (Fig. 1B). The small nuclear RNA U6 was relatively
unchanged by these stimuli (Fig. 1C), whereas the poly(I:C) and
IFN- target gene IP10 was induced by both (Fig. 1C). Some of
the macrophages generated for the experiment were also stained
with antigen-specific antibodies and analyzed by FACS to assay
the macrophage marker CD11b and up-regulation of the
poly(I:C) and IFN- target gene CD86 after 24 h of stimulation
(Fig. 1D). These data indicate that macrophages respond to viral
cues by strongly up-regulating miR-155, a miRNA that is known
from other studies to function as an oncogene (17, 18, 22–25).
miR-155 is found within the BIC gene (17) on chromosome 21
in humans and 16 in mice (26). The genomic structure of human
BIC consists of three exons, and its transcript is transcribed and
processed into two differently sized mRNA molecules through
alternative polyadenylation. However, BIC lacks a large ORF
and therefore is unlikely to encode a protein. Rather, its sole
function may be to give rise to miR-155 encoded within exon 3
(Fig. 2A). To monitor the kinetics of miR-155 induction, both
BIC mRNA and mature miR-155 were assayed over a 48-h time
course after poly(I:C) or IFN- stimulation of primary macro-
Fig. 1. Microarray analysis of miRNAs induced during the macrophage antiviral response. (A) WT murine macrophages were stimulated with medium (m), 2
g/ml poly(I:C) [p(I:C)], or 1,000 units/ml IFN- for 6 h. RNA was extracted and used to conduct a microarray analysis to determine the expression levels of 200
mammalian miRNAs. Data are presented on a scatter plot showing log10-transformed signal intensities for each probe on both channels for the Cy3-labeled media
controls and samples stimulated with Cy5-labeled IFN- (Left) or poly(I:C) (Right). (B) RNA used in A was analyzed by qPCR to assay expression of miR-155 and
in a separate experiment by Northern blot analysis under the same conditions. (C) RNA used in A was assayed by qPCR to detect expression of the small nuclear
RNA U6 as a loading control or IP10 mRNA to ensure equivalent stimulation by poly(I:C) and IFN-. (D) A portion of the macrophages generated in A were
stimulated with medium, poly(I:C), or IFN-and assayed for CD11b and CD86 expression by using FACS to ensure proper macrophage development and activation,
respectively.
Fig. 2. Kinetics of poly(I:C) and IFN- induction of BIC mRNA and mature
miR-155. (A) Unscaled depiction of the genomic structure of the human BIC
noncoding RNA gene and location of miR-155 (155) in exon 3. E, exon; I, intron.
(B) After stimulation with 2 g/ml poly(I:C) or 1,000 units/ml IFN-, macro-
phage expression of BIC mRNA was analyzed over a 48-h time course by
reverse transcription with an oligonucleotide dT primer followed by detection
using PCR and agarose gel electrophoresis. Primers were designed to target
BIC sequences extending outside of miR-155. L32 mRNA detection is included
as a control. (C) RNA from B was also used to assay mature miR-155 by qPCR
over a 48-h time course.









phages. In response to poly(I:C), BIC mRNA became detectable
by 2 h, remained elevated to 8 h, and was still present at reduced
levels by 24 and 48 h after stimulation (Fig. 2B). miR-155
induction by poly(I:C) followed a similar pattern of expression as
BIC, with the exception of remaining at its highest levels at the
24- and 48-h time points (Fig. 2C). IFN- did not induce BIC
mRNA by 2 h, but it was detected by 8 h and was nearly
undetectable by 24 and 48 h (Fig. 2B). IFN- induction of
miR-155 followed the same delayed pattern of induction as BIC,
reaching its highest levels by 8 h and slowly decreasing by 24 and
48 h after stimulation (Fig. 2C). These findings provide evidence
that the regulation of miR-155 levels involves BIC mRNA
up-regulation by poly(I:C) or IFN-. Furthermore, miR-155 is
an immediate early target gene of poly(I:C)-induced signaling,
whereas its induction is relatively delayed downstream from
IFN- stimulation.
TLR3 is a receptor for poly(I:C) (27). Therefore, other TLR
ligands were tested to determine whether they also could induce
miR-155. Macrophages were stimulated with either poly(I:C);
LPS, which signals through TLR4 (28, 29); hypomethylated
DNA (CpG), a TLR9 ligand (30); or Pam3CSK4, a synthetic
lipoprotein that activates TLR2 (31). After 6 h, RNA was
harvested from these cells and analyzed by Northern blotting
(Fig. 3A), or the same RNA was converted to cDNA and assayed
by qPCR (data not shown) to determine miR-155 levels. All four
TLR ligands tested induced strong expression of miR-155,
whereas miR-155 was not detected by Northern blotting in cells
treated with medium alone (Fig. 3A). Therefore, TLRs that are
known to recognize pathogen-associated molecular patterns
from both viruses and other pathogens can strongly induce
miR-155.
TLRs signal through the MyD88 family of adaptor proteins
(3). Of these adaptors, TLR2 and TLR9 signaling is known to
require MyD88, whereas TLR3 utilizes TRIF. Adaptors can also
play partially redundant roles; for instance, TLR4 signals
through either MyD88 or TRIF (3). To test the requirement of
these adaptors for TLR induction of miR-155, macrophages
deficient in either TRIF or MyD88 were stimulated with differ-
ent TLR ligands and miR-155 levels were assayed by qPCR after
6 h. CpG (TLR9)- or Pam3CSK4 (TLR2)-treated macrophages
required MyD88, but not TRIF, to induce miR-155, whereas
poly(I:C) (TLR3) required TRIF but not MyD88 (Fig. 3B).
TLR4 up-regulated miR-155 in the absence of either single
adaptor (Fig. 3B). Such results confirm the specificity of the TLR
ligands used and demonstrate that either MyD88- or TRIF-
dependent signaling pathways are sufficient to induce miR-155.
A subset of TLR-responsive genes require IFN- autocrine/
paracrine signaling for their induction (4). Because miR-155 is
up-regulated by both TLRs and IFN-, we tested whether TLR
induction of miR-155 required IFN- autocrine/paracrine sig-
naling. However, both WT and IFNAR/ macrophages in-
creased miR-155 expression in response to either poly(I:C), LPS,
CpG, or Pam3CSK4 as assayed by qPCR (Fig. 3C). These data
indicate that TLRs do not require IFN- production for early
up-regulation of miR-155.
Similar to IFN-, IFN- is produced in response to viral and
bacterial infections and plays an important role in macrophage
activation (32). IFN- also induced miR-155 in macrophages
after 6 h of stimulation (Fig. 4A Left). Because IFN induction of
BIC mRNA and mature miR-155 was delayed compared with
that of poly(I:C), it appeared that IFNs might use a protein
intermediate to up-regulate miR-155. We noted a recent study
identifying a role for TNF- autocrine/paracrine signaling after
IFN- stimulation of macrophages (33). Using TNFR1/ mac-
rophages, we found that IFN- and IFN- failed to up-regulate
miR-155 in the absence of TNFR1 signaling as compared with
the induction observed in WT cells (Fig. 4A Left). Furthermore,
TNF- was sufficient to induce miR-155 expression in a TNFR1-
dependent manner (Fig. 4A Right) and induced miR-155 with
faster kinetics than did IFN- [supporting information (SI) Fig.
6]. Furthermore, both IFN- and IFN- induced TNF- mRNA
expression (Fig. 4B Left), whereas IFN- induction of IP10
remained intact in the TNFR1/ macrophage (Fig. 4B Right),
demonstrating that these cells can still respond to IFN treatment.
Finally, whereas poly(I:C) induced TNF- expression (Fig. 4C
Left), this TLR3 ligand did not require TNF- autocrine signal-
ing to induce miR-155 by 6 h after stimulation (Fig. 4C Right).
Together, these findings identify TNF- as an inducer of miR-
155 and indicate that IFNs require TNF- autocrine/paracrine
signaling to up-regulate miR-155 in macrophages.
To identify downstream signaling pathways involved in miR-
155 induction, we conducted a promoter sequence analysis to
Fig. 3. TLRs induce miR-155 expression through MyD88- or TRIF-dependent
signaling pathways. (A) WT (Wt) murine macrophages were stimulated with
medium (m), 2 g/ml poly(I:C) [p(I:C)], 5 ng/ml LPS, 2 g/ml Pam3CSK4 (P3C),
or 100 nM CpG for 6 h and assayed by Northern blot analysis with a miR-155-
specific probe. (B) WT, MyD88/, or TRIF/ macrophages were stimulated
with medium, poly(I:C), LPS, CpG, or Pam3CSK4 for 6 h, and miR-155 expression
was assayed by qPCR. (C) WT or IFNAR/ macrophages were stimulated with
medium, poly(I:C), LPS, CpG, or Pam3CSK4 for 6 h, and miR-155 expression was
assayed by qPCR.
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identify transcription factor binding sites within the promoter
region of the BIC gene that are conserved between mouse and
human. A region extending 75 bp upstream from the tran-
scriptional start site exhibited 85% sequence homology be-
tween mouse and human and contained two consensus binding
sequences for AP-1 (data not shown). This transcriptional
complex is known to be activated by inflammatory stimuli, such
as TLR ligands and TNF-, and requires signaling by JNK (1).
To test whether the JNK pathway is involved in miR-155
induction, we stimulated macrophages that had been treated
with an inhibitor of JNK (sp600125) with poly(I:C) or TNF- for
4 h. Vehicle-treated cells up-regulated miR-155 levels by 4 h
after stimulation, whereas the JNK inhibitor blocked miR-155
induction by both stimuli in a dose-dependent manner (Fig. 5).
As a control, the ERK inhibitor uo126 did not reduce poly(I:C)
induction of miR-155 (data not shown). These findings suggest
that the JNK pathway is involved in the up-regulation of miR-155
expression in response to poly(I:C) or TNF-.
Discussion
Dysregulation of miRNA levels has been associated with several
types of cancers, including those involving leukocytes. However,
the ability of environmental factors, such as inflammatory
ligands, to alter miRNA expression is just beginning to be
explored. Our microarray screen identified miR-155 as the only
miRNA of the 200 we tested that was substantially induced by
either poly(I:C) and IFN-. In addition to poly(I:C), miR-155
was induced by other TLR ligands through either MyD88- or
TRIF-dependent signaling pathways, and by the cytokines
IFN- and IFN- through TNF- autocrine/paracrine signaling.
Therefore, our study identifies and characterizes miR-155 as a
component of the primary macrophage response to different
types of inflammatory mediators, expanding our initial obser-
vation that miR-155 is induced by LPS in human THP-1 mono-
cytes (21). BecausemiR-155 is known to function as an oncogene
(17, 18, 22–25), such findings have implications for both innate
immunity and cancer biology.
Although TLRs induced miR-155 as an immediate early gene,
IFN induction of miR-155 was weaker and exhibited delayed
kinetics because of the need for TNF- autocrine/paracrine
signaling. The existence of such a signaling loop was recently
described, when it was shown that TNFR1 was required for
IFN- induction of nitric oxide in macrophages (33). Such a
system enables IFNs to induce TNF- target genes, including
miR-155, in addition to the well established IFN-responsive
genes (34). Although it is presently unknown whether this
pathway also is relevant in other cell types besides macrophages
(35), it highlights the complexity of the cytokine networks that
respond after exposure to infectious pathogens.
The IFN system has long been known to provide all nucleated
cells with antiviral capabilities after infection (34). Although the
protein-encoding genes induced during this response have been
well studied, the involvement of miRNAs has not been investi-
gated. Interestingly, our microRNA array screen identified only
miR-155 as a substantial target of IFN- signaling in macro-
phages. As discussed earlier, the induction required TNF-
autocrine/paracrine signaling. These observations would suggest
that miRNAs may not be direct targets of the canonical JAK/
STAT pathway known to transactivate several hundred antiviral
genes in response to IFN signaling. However, whereas our screen
included 200 unique miRNAs, there are presently close to 500 in
the miRNA registry, leaving many to be tested. It is also possible
that a portion of the miRNAs analyzed are regulated at the RNA
processing level, and, therefore, their mature forms were not
detected. This phenomenon has recently been observed for
miR-138 in the brain (36). Such a scenario may require addi-
tional signals to activate processing and might only occur during
infection with a live, whole pathogen.
Fig. 4. IFNs induce miR-155 expression through TNF- autocrine/paracrine
signaling. (A) WT (Wt) and TNFR1/ murine macrophages were stimulated
with medium (m), 1,000 units/ml IFN-, 50 ng/ml IFN-, or 10 ng/ml TNF- for
6 h, and miR-155 was assayed by qPCR. (B) (Left) WT macrophages were
stimulated with medium, IFN-, or IFN- for 6 h, and TNF- mRNA was
analyzed by qPCR. (Right) WT and TNFR1/ macrophages were stimulated
with IFN- for 6 h and assayed for IP10 mRNA expression by qPCR. (C) (Left) WT
macrophages were stimulated with medium or 2 g/ml poly(I:C) for 6 h and
assayed for TNF- expression by qPCR. (Right) WT and TNFR1/macrophages
were stimulated with medium or poly(I:C) for 6 h, and miR-155 was assayed by
qPCR.
Fig. 5. Pharmacological inhibition of JNK blocks poly(I:C) and TNF- induc-
tion of miR-155. WT murine macrophages were pretreated for 30 min with
DMSO or sp600125 at 5 or 25 g/ml and subsequently stimulated with me-
dium, 2 g/ml poly(I:C), or 10 ng/ml TNF- in the presence of the vehicle or
inhibitor. After 4 h, RNA was collected, and miR-155 expression was assayed by
qPCR.









It will be of importance to determine which host mRNAs with
relevance to immunity are being regulated by miR-155, or
whether miR-155 can directly target viral genomes or transcripts,
as miR-32 has been shown to do (37). To date, the only
characterized target of miR-155 is the angiotensin II type I
receptor in fibroblasts (38). In addition to miR-155, we have
previously foundmiR-146 andmiR-132 at higher levels in human
THP-1 monocytes after exposure to LPS (21). Further charac-
terization of miR-146 revealed that it can attenuate expression
of the innate signaling proteins IRAK1 and TRAF6, identifying
a possible regulatory role for miR-146 during TLR signaling.
Although clearly defining the physiological role of miR-155 as
well as other miRNAs expressed in myeloid cells remains an
unfinished task, collectively, these findings provide evidence that
miRNAs are part of the antimicrobial gene program induced by
infectious pathogens.
Our data suggest that the JNK pathway, which activates the
AP-1 complex, is involved in miR-155 induction by both TLRs
and TNF-, presumably through transcriptional activation of the
miR-155 encoding BIC gene. Although both the human and
mouse promoter regions of BIC contain binding sites for AP-1
near the transcriptional start site, there are a few putative
binding sites for NF-B family members further upstream (ref.
39 and our unpublished data). However, the involvement of
NF-B in up-regulating miR-155 levels remains unclear. One
group reported that overexpression of an IB dominant active
protein does not block BCR mediated induction of BIC in
Ramos B cells (39), whereas another gene chip study identified
a reduction in BIC transcripts in response to inhibitors of IKK
administered to lymphoma cells with constitutively active NF-B
(40). As both JNK and NF-B have been implicated in mediating
oncogenesis (41, 42), miR-155 may prove to be an important
target of these transcription factors during this process.
Both miRNAs and microbially induced inflammation are
associated with cancer (8, 16). Our current findings suggest the
possibility that miR-155 could be a link between the two. The
miR-155-encoding gene BIC was originally identified as a com-
mon retroviral integration site of avian leukosis virus during
induction of B cell lymphomas in chickens, which exhibit high
BIC expression (22, 25). miR-155 also has been found at high
levels in human B cell lymphomas and other tumors (17, 18, 24,
39, 43), whereas enforced overexpression of miR-155 in mouse
B cells is sufficient to trigger murine B cell lymphoma (23). These
data demonstrate that inappropriate expression of miR-155 can
promote cancer, and it is therefore important to understand how
miR-155 levels are regulated. Although we show that a broad
range of inflammatory mediators can induce miR-155 in mac-
rophages and monocytes, B and T lymphocytes are known to
up-regulate miR-155 after BCR or TCR activation, respectively
(39, 44). Like macrophages, B and T cells also express a variety
of TLRs that could induce miR-155 expression and contribute to
both physiological and pathological responses. Furthermore, it
will be of interest to determine whether miR-155 is also involved
in cancers derived from myeloid cells, such as acute myeloid
leukemias.
The present findings identify up-regulation of miR-155 as a
consequence of exposure to a broad range of inflammatory
mediators, emphasizing that the avoidance of oncogenic trans-
formation is a key rationale for the need to rapidly resolve
inflammatory responses.
Materials and Methods
Cell Culture and Reagents. Bone marrow cells were isolated from
the tibias and femurs of mice as described (4). In short, RBCs
were lysed by using a RBC lysis buffer (Invitrogen, San Diego,
CA), and the remaining bone marrow cells were plated out in
DMEM containing 10% FBS, 100 units/ml penicillin, and 100
units/ml streptomycin and supplemented with macrophage col-
ony-stimulating factor-conditioned medium at a previously es-
tablished concentration. Cells were cultured in a humidified
incubator with 5%CO2 at 37°C. After 7 days of culture, a portion
of the macrophages were stained with specific antibodies and
analyzed by FACS to ensure proper differentiation (CD11bF4/
80CD11c) and subsequently used for experiments. Primary
macrophages were stimulated by using fresh DMEM containing
one of the following: 5 ng/ml 055-B5 LPS (Sigma, St. Louis,MO),
100 nM CpG 1668 oligonucleotides (Invitrogen), 2 g/ml
Pam3CSK4 (Invitrogen), 2 g/ml poly(I:C) (Amersham Phar-
macia, Piscataway, NJ), 1,000 units/ml mIFN- (R&D Systems,
Minneapolis, MN), 50 ng/ml mIFN- (Ebioscience, San Diego,
CA), or 10 ng/ml mTNF- (Roche, Basel, Switzerland). The
chemical inhibitors sp600125 and uo126 were dissolved in
DMSO and used at various concentrations (Calbiochem, La
Jolla, CA).
Mice.WT,MyD88/, TRIF/, IFNAR/, and TNFR1/mice,
all of which are on a C57BL/6 genetic background, were bred and
housed in the University of California Division of Laboratory
Animal Medicine facility and killed according to established pro-
tocols approved by the Animal Research Committee.
Microarray Analysis. The microarray screening procedure was the
same as described (21). RNA from stimulated macrophages was
collected by using the mirVana RNA isolation kit (Ambion,
Austin, TX); 30 g was enriched for small RNAs, tailed by using
the mirVana miRNA labeling kit (Ambion), and labeled with
either Cy3 (control samples) or Cy5 (stimulated samples) fluo-
rescent dyes (Amersham Pharmacia). The stimulated and con-
trol samples were next mixed and incubated for 14 h withmiRNA
array slides. The epoxy-coated slides (Schott–Nexterion, Louis-
ville, KY) were prepared in quadruplicate by using robotics for
the spotting of 200 mouse and human sequences complimentary
to different mammalian miRNAs (mirVana miRNA Probe Set;
Ambion). After hybridization, microarrays were scanned with a
GenePix 4200A scanner (Axon Instruments, Foster City, CA) by
using Gene Pix 5.0 software (Axon Instruments). Raw data were
imported into the Resolver gene expression data analysis system
version 4.0 (Rosetta Biosoftware, Seattle, WA) for further
processing.
Messenger RNA Detection. Total RNA was harvested from bone-
marrow-derived macrophages by using the TRIzol Reagent
(Invitrogen), and 1 g of total RNA was converted to cDNA by
using iScript (Invitrogen) both according to the manufacturer’s
protocol. Sybergreen-based real-time qPCR was performed by
using the 7300 Real-Time PCR system (Applied Biosystems,
Foster City, CA) and gene-specific primers for TNF-, IP10, and
L32 as described (4, 45). All qPCR data has been normalized to
L32 values. To detect the expression of BIC and L32 mRNA,
cDNA was subjected to PCR and run out on a 2% agarose gel
containing ethidium bromide at 1 g/ml. The primer sequences
used to detect BIC were 5-ttggcctctgactgactcct-3 (forward) and
5-gcagggtgactcttggactt-3 (reverse).
MicroRNA Detection. For detection of miR-155 by Northern
blotting, RNA was extracted by using the TRIzol reagent
according to the manufacturer’s protocol (Invitrogen). Fifteen
micrograms of total RNA was electrophoretically separated on
a 12% polyacrylamide denaturing gel, and tRNA was visualized
by using ethidium bromide staining to ensure the quality and
relative amount of the RNA. Total RNA was next transferred to
a GeneScreenPlus membrane (PerkinElmer, Boston, MA) by
using a semidry Transblot electrophoresis apparatus (Bio-Rad,
Hercules, CA). The RNA was crosslinked to the membrane by
using UV radiation. Hybridization was carried out by using
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ULTRAHybOligo solution according to the manufacturer’s
instructions (Ambion). The probe sequence was complementary
to the mature form of miR-155, and was labeled with -32P. After
being washed, the membranes were imaged by using a STORM
phosphorimager. Detection of miR-155 and U6 was also per-
formed by using the mirVana qRT-PCR miRNA detection kit
according to the manufacturer’s instructions (Ambion).
Flow Cytometry. To detect expression of CD86 or CD11b, RBC-
depleted splenocytes were stained in FACS buffer (1 PBS/
0.1% BSA/2% FBS/0.1% normal mouse serum) by using phy-
coerythrin-conjugated anti-CD11b or FITC-conjugated anti-
CD86 (Ebiosciences, San Diego, CA) and fixed with
paraformaldehyde (1% final concentration). Surface expression
was assayed by using a FACScan flow cytometer (Becton
Dickenson, Franklin Lakes, NJ).
Promoter Analysis. Promoter analysis software from Genomatix
(Munich, Germany) was used to identify putative binding sites
within the BIC promoter.
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